Q.J. Sheng 1 , Y. Ding 1 , X.G. Dou 1 1 Department of Infectious Disease, Shengjing Hospital Affiliated to China Medical University, Shenyang, 110004, China Objectives: To study a kinetics of hepatitis B virus during 12-week and 24-week of treatment with enticavir (ENT); To compare the detecting results of HBVDNA levels from different detection reagents. Methods: Thirty-seven cases of chronic HBV infections were selected randomly, treated with daily dose of ENT 0.5-1.0mg (0.5mg for nucleoside-naïve patients, 1.0mg for lamivuding-refractory patients). Evaluation indexes: Serum HBVDNA, HBV serological markers, and liver function tests. HBVDNA levels were measured by PCR assay, using both domestic reagents and Roche Cobas Amplicor,. The lower limits of measure level of HBVDNA were 1000 copies/ml and 300 copies/ml, respectively. Results: Mean baseline of HBVDNA was 5.24log10copies/ml for detection using domestic reagents and 5.70log10copies/ml for that using Roche Cobas Amplicor, (P>0.05). The ratios of cases with undetectable (<1000 copies/ml) HBVDNA at week-12 and week-24 were 46.2% and 72.9%, respectively. The ratios of cases with undetectable (<300 copies/ml) HBVDNA at week-24 were 54.5%. Among the cases whose HBVDNA were lower than 1000 copies/ml(using domestic reagents), the ratio of HBVDNA lower than 300 copies/ml(using Roche Cobas Amplicor) was 94.7%. Conclusions: ENT can suppress HBV DNA rapidly no matter the patients with ALT elevation or not. There is a concordance on HBVDNA levels detection between domestic reagents and Roche Cobas Amplicor. Background The study on the effect of nucleoside analogue therapy on the quantity of hepatocellular cccDNA and tDNA and sera HBV DNA, HBsAg to probe reliable marks for evaluation of therapy endpoint. Methods The quantity of hepatocellular cccDNA and tDNA and sera HBVDNA were assayed by FQ-PCR, and sera HBsAg by ELISA in 4 CHB patients over 2 years nucleoside analogue therapy satisfied the China criteria of therapy endpoint (therapy group)and 12 CHB patients without antiviral therapy and sera HBVDNA<10 3 copies/ml(control group). Results: The quantity of hepatocellular cccDNA, tDNA and sera HBVDNA, HBsAg in therapy group were lower than that of control group,but low level hepatocellular cccDNA in therapy group could be detected. Conclusion: Long term nucleoside analogue therapy may consume hepatocellular cccDNA with decreasing of hepatocellular tDNA and sera HBVDNA, HBsAg; Although the patients have satisfied the China criteria of therapy endpoint, low level of hepatocellular HBVcccDNA were detected, cessation of therapy may cause relapse.